SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a clinical-stage pharmaceutical company, has announced their subsidiary MitoCareX’s recent success in demonstrating the significant role of the SLC25 carrier protein in fighting Non-Small Cell Lung Cancer (NSCLC). The discovery, critical for a cancer type that represents a substantial portion of global cancer cases, was achieved using advanced 3D tumor models and genetic manipulation. Further efforts include the development of an AI model to streamline the discovery of new anti-cancer molecules targeting the SLC25 protein.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
